Endovascular treatment in anterior circulation stroke beyond 6.5 hours after onset or time last seen well: results from the MR CLEAN Registry.


Journal

Stroke and vascular neurology
ISSN: 2059-8696
Titre abrégé: Stroke Vasc Neurol
Pays: England
ID NLM: 101689996

Informations de publication

Date de publication:
12 2021
Historique:
received: 18 12 2020
revised: 03 03 2021
accepted: 10 03 2021
pubmed: 9 4 2021
medline: 6 4 2022
entrez: 8 4 2021
Statut: ppublish

Résumé

Randomised controlled trials with perfusion selection have shown benefit of endovascular treatment (EVT) for ischaemic stroke between 6 and 24 hours after symptom onset or time last seen well. However, outcomes after EVT in these late window patients without perfusion imaging are largely unknown. We assessed their characteristics and outcomes in routine clinical practice. The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands Registry, a prospective, multicentre study in the Netherlands, included patients with an anterior circulation occlusion who underwent EVT between 2014 and 2017. CT perfusion was no standard imaging modality. We used adjusted ordinal logistic regression analysis to compare patients treated within versus beyond 6.5 hours after propensity score matching on age, prestroke modified Rankin Scale (mRS), National Institutes of Health Stroke Scale, Alberta Stroke Programme Early CT Score (ASPECTS), collateral status, location of occlusion and treatment with intravenous thrombolysis. Outcomes included 3-month mRS score, functional independence (defined as mRS 0-2), and death. Of 3264 patients who underwent EVT, 106 (3.2%) were treated beyond 6.5 hours (median 8.5, IQR 6.9-10.6), of whom 93 (87.7%) had unknown time of stroke onset. CT perfusion was not performed in 87/106 (80.2%) late window patients. Late window patients were younger (mean 67 vs 70 years, p<0.04) and had slightly lower ASPECTS (median 8 vs 9, p<0.01), but better collateral status (collateral score 2-3: 68.3% vs 57.7%, p=0.03). No differences were observed in proportions of functional independence (43.3% vs 40.5%, p=0.57) or death (24.0% vs 28.9%, p=0.28). After matching, outcomes remained similar (adjusted common OR for 1 point improvement in mRS 1.04, 95% CI 0.56 to 1.93). Without the use of CT perfusion selection criteria, EVT in the 6.5-24-hour time window was not associated with poorer outcome in selected patients with favourable clinical and CT/CT angiography characteristics. randomised controlled trials with lenient inclusion criteria are needed to identify more patients who can benefit from EVT in the late window.

Sections du résumé

BACKGROUND
Randomised controlled trials with perfusion selection have shown benefit of endovascular treatment (EVT) for ischaemic stroke between 6 and 24 hours after symptom onset or time last seen well. However, outcomes after EVT in these late window patients without perfusion imaging are largely unknown. We assessed their characteristics and outcomes in routine clinical practice.
METHODS
The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands Registry, a prospective, multicentre study in the Netherlands, included patients with an anterior circulation occlusion who underwent EVT between 2014 and 2017. CT perfusion was no standard imaging modality. We used adjusted ordinal logistic regression analysis to compare patients treated within versus beyond 6.5 hours after propensity score matching on age, prestroke modified Rankin Scale (mRS), National Institutes of Health Stroke Scale, Alberta Stroke Programme Early CT Score (ASPECTS), collateral status, location of occlusion and treatment with intravenous thrombolysis. Outcomes included 3-month mRS score, functional independence (defined as mRS 0-2), and death.
RESULTS
Of 3264 patients who underwent EVT, 106 (3.2%) were treated beyond 6.5 hours (median 8.5, IQR 6.9-10.6), of whom 93 (87.7%) had unknown time of stroke onset. CT perfusion was not performed in 87/106 (80.2%) late window patients. Late window patients were younger (mean 67 vs 70 years, p<0.04) and had slightly lower ASPECTS (median 8 vs 9, p<0.01), but better collateral status (collateral score 2-3: 68.3% vs 57.7%, p=0.03). No differences were observed in proportions of functional independence (43.3% vs 40.5%, p=0.57) or death (24.0% vs 28.9%, p=0.28). After matching, outcomes remained similar (adjusted common OR for 1 point improvement in mRS 1.04, 95% CI 0.56 to 1.93).
CONCLUSIONS
Without the use of CT perfusion selection criteria, EVT in the 6.5-24-hour time window was not associated with poorer outcome in selected patients with favourable clinical and CT/CT angiography characteristics. randomised controlled trials with lenient inclusion criteria are needed to identify more patients who can benefit from EVT in the late window.

Identifiants

pubmed: 33827915
pii: svn-2020-000803
doi: 10.1136/svn-2020-000803
pmc: PMC8717786
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

572-580

Investigateurs

Jan Albert Vos (JA)
Kars C J Compagne (KCJ)
Manon Kappelhof (M)
Josje Brouwer (J)
Sanne J den Hartog (SJ)
Wouter H Hinsenveld (WH)
Bob Roozenbeek (B)
Jonathan M Coutinho (JM)
Marianne A A van Walderveen (MAA)
Julie Staals (J)
Jeannette Hofmeijer (J)
Jasper M Martens (JM)
Sebastiaan F de Bruijnl (SF)
C Lukas (C)
H van Dijk (H)
Bart van der Worp (BV)
Rob H Lo (RH)
Ewoud J van Dijk (EJ)
D Boogaarts Hieronymus (DB)
J de Vries (J)
Paul L M de Kort (PLM)
Julia van Tuijl (JV)
Jo P Peluso (JP)
Puck Fransen (P)
Jan S P van den Berg (JSP)
Boudewijn A A M van Hasselt (BAAM)
Leo A M Aerden (LAM)
René J Dallinga (RJ)
Maarten Uyttenboogaart (M)
Omid Eschgi (O)
Reinoud P H Bokkers (RPH)
Tobien H C M L Schreuder (THCML)
Roel J J Heijboer (RJJ)
Koos Keizer (K)
Lonneke S F Yo (LSF)
Heleen M den Hertog (HM)
Emiel J C Sturm (EJC)
Paul J A M Brouwers (PJAM)
Marieke E S Sprengers (MES)
Sjoerd F M Jenniskens (SFM)
René van den Berg (RVD)
Albert J Yoo (AJ)
Ludo F M Beenen (LFM)
Alida A Postma (AA)
Stefan D Roosendaal (SD)
Bas F W van der Kallen (BFW)
Ido R van den Wijngaard (IR)
Adriaan C G M van Es (ACGM)
Joost Bot (J)
Pieter-Jan van Doormaal (PV)
Anton Meijer (A)
Elyas Ghariq (E)
P Marc (P)
G van Proosdij (G)
Menno Krietemeijer (M)
Dick Gerrits (D)
Wouter Dinkelaar (W)
Auke P A Appelman (APA)
Bas Hammer (B)
Sjoert Pegge (S)
Anouk van der Hoorn (AV)
Saman Vinke (S)
Wouter J Schonewille (WJ)
Naziha El Ghannouti (NE)
Martin Sterrenberg (M)
Wilma Pellikaan (W)
Rita Sprengers (R)
Marjan Elfrink (M)
Michelle Simons (M)
Marjolein Vossers (M)
Joke de Meris (J)
Tamara Vermeulen (T)
Annet Geerlings (A)
Gina van Vemde (GV)
Tiny Simons (T)
Gert Messchendorp (G)
Nynke Nicolaij (N)
Hester Bongenaar (H)
Karin Bodde (K)
Sandra Kleijn (S)
Jasmijn Lodico (J)
Hanneke Droste (H)
Maureen Wollaert (M)
Sabrina Verheesen (S)
D Jeurrissen (D)
Erna Bos (E)
Yvonne Drabbe (Y)
Michelle Sandiman (M)
Nicoline Aaldering (N)
Berber Zweedijk (B)
Jocova Vervoort (J)
Eva Ponjee (E)
Sharon Romviel (S)
Roger R M Harmsma (RRM)
Daan Muijres (D)
Olvert A Berkhemer (OA)
M M Anna Boers (MMA)
J Huguet (J)
P F C Groot (PFC)
Marieke A Mens (MA)
Katinka R van Kranendonk (KR)
Kilian M Treurniet (KM)
Manon L Tolhuisen (ML)
Heitor Alves (H)
Annick J Weterings (AJ)
Eleonora L F Kirkels (ELF)
Eva J H F Voogd (EJHF)
Lieve M Schupp (LM)
Sabine Collette (S)
Adrien E D Groot (AED)
Natalie E LeCouffe (NE)
Praneeta R Konduri (PR)
Haryadi Prasetya (H)
Nerea Arrarte-Terreros (N)
Lucas A Ramos (LA)

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Erasmus MC received funds from Stryker and Bracco Imaging by DWJD. MUMC received funds from Stryker and Codman for consultations by WHvZ. WHvZ and RJvO are principal investigators for the MR CLEAN-LATE trial. R-JBG and FAVP are coordinating researchers for MR CLEAN-LATE. CBLMM received funds from TWIN Foundation (related to this project, paid to institution) and from CVON/Dutch Heart Foundation, Stryker, European Commission, Health Evaluation Netherlands (unrelated; all paid to institution). YBWEMR, CBLMM and IGHJ are shareholders of Nico.lab, a company that focuses on the use of artificial intelligence for medical imaging analysis. RL reports institutional fees from Ischamaview for consultancy. The other authors had no conflicting interests.

Références

N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Stroke. 2021 Jan;52(2):491-497
pubmed: 33430634
Stroke. 2015 Oct;46(10):2981-6
pubmed: 26330447
Lancet. 2000 May 13;355(9216):1670-4
pubmed: 10905241
BMJ. 2018 Mar 9;360:k949
pubmed: 29523557
J Neurointerv Surg. 2019 Feb;11(2):200-203
pubmed: 30097484
BMJ. 2017 May 3;357:j1710
pubmed: 28468840
J Neurointerv Surg. 2017 Oct;9(10):915-916
pubmed: 27471187
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
J Neurointerv Surg. 2020 Sep;12(9):842-847
pubmed: 31772044
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
J Neurointerv Surg. 2014 Mar;6(2):83-6
pubmed: 23390038
AJNR Am J Neuroradiol. 2020 Jan;41(1):129-133
pubmed: 31806593
Stroke. 2019 Dec;50(12):3465-3470
pubmed: 31665993
Int J Stroke. 2016 Aug;11(6):701-16
pubmed: 27462090
AJNR Am J Neuroradiol. 2009 Mar;30(3):525-31
pubmed: 19147716
J Neurointerv Surg. 2020 Nov 25;:
pubmed: 33239306
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Stroke. 2015 Oct;46(10):3020-35
pubmed: 26123479
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
Eur J Neurol. 2018 Aug;25(8):1093-1099
pubmed: 29667266
Trials. 2021 Feb 24;22(1):160
pubmed: 33627168
Circulation. 2018 Jul 17;138(3):232-240
pubmed: 29581124
Stroke. 1989 Jul;20(7):864-70
pubmed: 2749846
Front Neurol. 2014 Mar 26;5:35
pubmed: 24723908
Stroke. 2018 Apr;49(4):1015-1017
pubmed: 29581344
J Neurointerv Surg. 2019 Jul;11(7):670-674
pubmed: 30530773
J Neurointerv Surg. 2018 Nov;10(11):1043-1046
pubmed: 29459367
Stroke. 2016 Mar;47(3):768-76
pubmed: 26903582
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852

Auteurs

Luuk Dekker (L)

Neurology, Leiden University Medical Centre, Leiden, The Netherlands.

Esmee Venema (E)

Neurology, Erasmus MC, Rotterdam, The Netherlands e.venema@erasmusmc.nl.
Public Health, Erasmus MC, Rotterdam, The Netherlands.

F Anne V Pirson (FAV)

Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Charles B L M Majoie (CBLM)

Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Location AMC, Amsterdam, The Netherlands.

Bart J Emmer (BJ)

Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Location AMC, Amsterdam, The Netherlands.

Ivo G H Jansen (IGH)

Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Location AMC, Amsterdam, The Netherlands.

Maxim J H L Mulder (MJHL)

Neurology, Erasmus MC, Rotterdam, The Netherlands.

Robin Lemmens (R)

Neurology, University Hospitals Leuven, Leuven, Belgium.
Neurosciences, Experimental Neurology and Leuven Brain Institute, University of Leuven, Leuven, Belgium.
VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.

Robert-Jan B Goldhoorn (RB)

Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Marieke J H Wermer (MJH)

Neurology, Leiden University Medical Centre, Leiden, The Netherlands.

Jelis Boiten (J)

Neurology, Haaglanden Medical Centre, Den Haag, The Netherlands.

Geert J Lycklama À Nijeholt (GJ)

Radiology, Haaglanden Medical Centre, Den Haag, The Netherlands.

Yvo B W E M Roos (YBWEM)

Neurology, Amsterdam University Medical Centre, Location AMC, Amsterdam, The Netherlands.

Adriaan C G M van Es (ACGM)

Radiology, Haaglanden Medical Centre, Den Haag, The Netherlands.
Radiology, Leiden University Medical Centre, Leiden, The Netherlands.

Hester F Lingsma (HF)

Public Health, Erasmus MC, Rotterdam, The Netherlands.

Diederik W J Dippel (DWJ)

Neurology, Erasmus MC, Rotterdam, The Netherlands.

Wim H van Zwam (WH)

Radiology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Robert J van Oostenbrugge (RJ)

Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Ido R van den Wijngaard (IR)

Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
Neurology, Haaglanden Medical Centre, Den Haag, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH